Recently, Beijing Beilu Pharmaceutical Co., Ltd received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration (NMPA).
On March 11th, the National Medical Products Administration (NMPA) issued the “Notice Recognizing Excellent Units in the National Adverse Drug Reactions Monitoring and Evaluation 2020”.